Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

NCT00198588

Heparin-Induced Thrombocytopenia

COMPLETED PHASE3

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

NCT00861692

Heparin-induced Thrombocytopenia Type II

COMPLETED PHASE2

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

NCT06281327

Immune Thrombocytopenia Treatment

RECRUITING PHASE2

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

NCT06838962

Immune Thrombocytopenia Treatment

RECRUITING PHASE2

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

NCT06168851

Immune Thrombocytopenia Treatment

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Argatroban

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females ages birth to 16 years,inclusive, at enrollment. For neonates, the minimum corrected gestational age should be 37 weeks.
* Documented HIT defined as a fall in platelet count to less than 100,000/uL or a \>=50% decrease in platelets after the initiation of heparin therapy with no apparent explanation other than HIT, or
* Require anticoagulation and have a documented history of a positive HIT test in the absence of current thrombocytopenia (i.e. patients at risk for HIT), or
* In the opinion of the investigator, require alternative anticoagulation due to an underlying condition, such as AT-III deficiency or heparin resistance.
* Signed (written) informed consent or assent by the patient (if age appropriate) and the patient's parent or guardian.

Criteria for Exclusion:

* Any condition which, in the investigator's opinion, would contraindicate the use of Argatroban or would endanger the patient if he/she participated in this trial.
* Unexplained aPTT \> 2 times the upper limit of normal at baseline, in the absence of heparin.
* International Normalized Ratio (INR) \>1.6 at baseline in the absence of warfarin.
* Known clinical site of bleeding or predisposition to bleeding (e.g., GI bleed, hematuria, hemorrhagic CVA,retroperitoneal hematoma, diabetic retinopathy, hemorrhagic pericardial effusion, or hemorrhagic pleural effusion. Patients who have a known clinical site of bleeding may be enrolled if the investigator deems the risk of continued thrombosis to outweigh the potential bleeding risk.
* Any patient who has received any investigational medication within 30 days prior to the first dose of study medication or who is scheduled to receive an investigational drug other than Argatroban during the course of the study.
* Known hypersensitivity to Argatroban or chemically related compounds.
* Females of childbearing potential who are pregnant (positive serum beta-HCG), breast feeding, or sexually active and not taking adequate contraceptive precautions (e.g. IUD or oral contraceptives).
* Any patient receiving a thrombolytic medication (e.g. tPA).
* Any neonate with a corrected gestational age of \< or = 44 weeks and bleeding in the head (Grade I or above) as determined by head ultrasound.

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No